AbbVie Acquires Mavupharma for its STING (STimulator of INterferon Genes) Modulators to Treat Cancer
Shots:
- AbbVie has acquired Mavupharma to develop STING modulators and to advance Mavupharma's lead candidate MAVU-104 towards clinical study
- The focus of the acquisition is to bolster AbbVie’s early-stage oncology portfolio with the addition of Mavupharma’s platform which involves the development of transformative therapies for cancer patients
- MAVU-104 is an orally administered ENPP1 inhibitor allowing highly controlled enhancement of STING signaling in tumors without the need for injections
Click here to read full press release/ article | Ref: AbbVie | Image: Mavupharma
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com